Thiazolidinediones and Heart Failure

Singh, Sonal, Loke, Yoon K., Furberg, Curt D.·2007·Diabetes Care
DOI 10.2337/dc07-0141

Cited by (261)

Items 101–200 of 261

  1. Pharmacogenomics of Metabolic Effects of Rosiglitazone
    Ond⊘řej Šeda, Lucie Šedová, Olena Oliyarnyk, Ludmila Kazdová, Drahomíra K⊘enová, Gilles Corbeil, Pavel Hamet, Johanne Tremblay, Vladimír K⊘en · 2008 · Pharmacogenomics
  2. Pioglitazone: an agent which reduces stroke, myocardial infarction and death and is also a key component of the modern paradigm for the optimum management of type 2 diabetes
    Robert E. J. Ryder · 2011 · The British Journal of Diabetes
  3. Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients
    Syed Shahzad Hasan, Chia Siang Kow, Amie Bain, Sallianne Kavanagh, Hamid A. Merchant, Muhammad Abdul Hadi · 2020 · Expert Opinion on Pharmacotherapy
  4. 18:0 Lyso PC, a natural product with potential PPAR-γ agonistic activity, plays hypoglycemic effect with lower liver toxicity and cardiotoxicity in db/db mice
    Yiming Ma, Xinyi Du, Dandan Zhao, Kegong Tang, Xiaona Wang, Shaoting Guo, Xiaobei Li, Song Mei, Na Sun, Jiaqi Liu et al. · 2021 · Biochemical and Biophysical Research Communications
  5. The Role of Growth Hormone and Insulin Growth Factor 1 in the Development of Non-Alcoholic Steato-Hepatitis: A Systematic Review
    Luca Cristin, Amalia Montini, Alessandro Martinino, Juan Pablo Scarano Pereira, Francesco Giovinazzo, Salvatore Agnes · 2023 · Cells
  6. Comparison of Pooled Risk Estimates for Adverse Effects from Different Observational Study Designs: Methodological Overview
    Su Golder, Yoon Kong Loke, Martin Bland · 2013 · PLoS ONE
  7. A new “Comparative Effectiveness” assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone
    Richard L. Tannen, Dawei Xie, Xingmei Wang, Menggang Yu, Mark G. Weiner · 2012 · Pharmacoepidemiology and Drug Safety
  8. Cardiovascular Disease and Diabetes
    Heather Mangiapane · 2012 · Advances in experimental medicine and biology
  9. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis
    Ishaque Hameed, Javeria Hayat, Shayan Marsia, Syed Abdus Samad, Rafay Khan, Omer Mustafa Siddiqui, Mohammad Omer Khan, Shanza Malik, Kaneez Fatima, Marat Fudim et al. · 2023 · Clinics and Research in Hepatology and Gastroenterology
  10. Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study
    Joonsang Yoo, Jimin Jeon, Minyoul Baik, Jinkwon Kim · 2023 · Cardiovascular Diabetology
  11. Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study
    Erin D. Roe, Bindu Chamarthi, Philip Raskin · 2015 · Journal of Diabetes Research
  12. Development of Heart Failure in Medicaid Patients with Type 2 Diabetes Treated with Pioglitazone, Rosiglitazone, or Metformin
    Ian Michael Breunig, Fadia Tohme Shaya, Mary Lynn McPherson, Søren Snitker · 2014 · Journal of Managed Care Pharmacy
  13. Differences in effects of insulin glargine or pioglitazone added to oral anti-diabetic therapy in patients with type 2 diabetes
    Mozhgan Dorkhan, Anders H. Frid, Leif Groop · 2008 · Diabetes Research and Clinical Practice
  14. Études pharmaco-épidémiologiques : quels niveaux de preuve et comment les atteindre ?
    Maryse Lapeyre‐Mestre, Claudine Sapède, Nicholas D Moore, Pascal Bilbault, Patrick Blin, Damien Chopy, David Evans, François Gueyffier, Laure Lacoin, Muriel Malbezin et al. · 2013 · Therapies
  15. Insulin Resistance in Skeletal Muscle Selectively Protects the Heart in Response to Metabolic Stress
    Dandan Jia, Jun Zhang, Xueling Liu, John-Paul Andersen, Zhenjun Tian, Jia Nie, Yuguang Shi · 2021 · Diabetes
  16. The contributions of oxidative stress, oxidised lipoproteins and AMPK towards exercise-associated PPARγ signalling within human monocytic cells
    N. A. Davies, Laura J. Watkeys, Lee Butcher, S. Potter, Michael G. Hughes, Hannah Jayne Moir, Keith Morris, Andrew W. Thomas, R Webb · 2014 · Free Radical Research
  17. C-terminus of HSC70-Interacting Protein (CHIP) Inhibits Adipocyte Differentiation via Ubiquitin- and Proteasome-Mediated Degradation of PPARγ
    Jung-Hoon Kim, Soyeon Shin, Jinho Seo, Eun‐Woo Lee, Manhyung Jeong, Min-Sik Lee, Hyun-Ji Han, Jaewhan Song · 2017 · Scientific Reports
  18. A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus
    Bo‐Yeon Kim, Hyuk‐Sang Kwon, Suk Kyeong Kim, Jung-Hyun Noh, Hyeong-Kyu Park, Hyeong-Kyu Park, Kee-Ho Song, Jong Chul Won, Jae Myung Yu, Jae Hyuk Lee et al. · 2022 · Diabetes & Metabolism Journal
  19. Pharmacoepidemiology Studies: what Levels of Evidence and how can They be Reached?
    Maryse Lapeyre‐Mestre, Claudine Sapède, Nicholas D Moore, Pascal Bilbault, Patrick Blin, Damien Chopy, David Evans, François Gueyffier, Laure Lacoin, Muriel Malbezin et al. · 2013 · Therapies
  20. Should Antidiabetic Treatment of Type 2 Diabetes in Patients with Heart Failure Differ from that in Patients Without?
    Anselm Kai Gitt, Martin Halle, Markolf Hanefeld E, Monika Kellerer, Nikolaus Marx, Juris Jendrik Meier, Petra‐Maria Schumm‐Draeger, Peter Bramlage, Diethelm Tschöpe · 2012 · European Journal of Heart Failure
  21. The safety of rosiglitazone in the treatment of Type 2 diabetes
    Sonal Singh, Yoon Kong Loke · 2008 · Expert Opinion on Drug Safety
  22. Relationship between natriuretic peptides and echocardiography parameters in patients with poorly regulated type 2 diabetes
    Magnus Dencker, Martin Stagmo, Mozhgan Dorkhan · 2010 · Vascular Health and Risk Management
  23. Safety and efficacy of rosiglitazone in the elderly diabetic patient
    Adie Viljoen · 2009 · Vascular Health and Risk Management
  24. Hematological and Serum Biochemical Analysis of Streptozotocin-Induced Insulin Dependent Diabetes Mellitus in Male Adult Wistar Rats
    Nima Yakhchalian, Nasim mohammadian, Kazem Hatami, Hamed Nosrati, Namdar Yousofvand · 2018 · bioRxiv (Cold Spring Harbor Laboratory)
  25. White adipose tissue mitochondrial bioenergetics in metabolic diseases
    Rugivan Sabaratnam, Didde Riisager Hansen, Per Svenningsen · 2023 · Reviews in Endocrine and Metabolic Disorders
  26. A web-based scoping review assessing the influence of smoking and smoking cessation on antidiabetic drug meabolism: implications for medication efficacy
    Carlo Maria Bellanca, Egle Augello, Giulia Di Benedetto, Chiara Burgaletto, Anna Flavia Cantone, Giuseppina Cantarella, Renato Bernardini, Riccardo Polosa, the DiaSmokeFree Working Group · 2024 · Frontiers in Pharmacology
  27. Personalized Management of Type 2 Diabetes
    Patricia R. Peter, Beatrice C. Lupsa · 2019 · Current Diabetes Reports
  28. Diabetes mellitus and heart failure - an overview of epidemiology and management
    V. Baliga, Robert J. Sapsford · 2015
  29. Sixty Years of Drug Discovery for Type 2 Diabetes: Where Are We Now?
    John C. Clapham · 2019 · Methods in molecular biology
  30. Marine oils: Complex, confusing, confounded?
    Benjamin B. Albert, David Cameron‐Smith, Manohar L. Garg, José G. B. Derraik, Paul Leslie Hofman, Wayne S. Cutfield · 2016 · Journal of Nutrition & Intermediary Metabolism
  31. Management of newly treated diabetes in Medicare beneficiaries with and without heart failure
    Lauren Beth Cooper, Xiaojuan Mi, Robert John Mentz, Jennifer B. Green, Kevin Joseph Anstrom, Adrian F. Hernandez, Lesley H. Curtis · 2016 · Clinical Cardiology
  32. Reducing the Burden of Mortality in Older People With Diabetes: A Review of Current Research
    Angus Forbes · 2020 · Frontiers in Endocrinology
  33. Thiazolidinediones and cardiovascular events in high-risk patients with type-2 diabetes mellitus: a comparison with other oral antidiabetic agents.
    Fadia Tohme Shaya, Kevin Lu, Kyongsei Sohn, Matthew R. Weir · 2009 · Europe PMC (PubMed Central)
  34. Systematic assessment of benefits and risks: study protocol for a multi-criteria decision analysis using the Analytic Hierarchy Process for comparative effectiveness research
    Nisa M. Maruthur, Susan M. Joy, James G. Dolan, Jodi B Segal, Hasan M Shihab, Sonal Singh · 2013 · F1000Research
  35. Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database
    Stephanie Berthet, Pascale Olivier, Jean‐Louis Montastruc, Maryse Lapeyre‐Mestre · 2011 · BMC Clinical Pharmacology
  36. Pharmacoepidemiology in older people: Purposes and future directions
    Marie‐Laure Laroche, Caroline Sirois, Emily Reeve, Danijela Gnjidic, Lucas Morin · 2019 · Therapies
  37. Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: Rationale and design of the tirzepatide treatment on coronary atherosclerosis progression: The (T-Plaque) randomized-controlled trial design
    Hossein Hamidi, Marziyeh Bagheri, Travis Benzing, Srikanth Krishnan, Sina Kianoush, Keishi Ichikawa, Ahmed K. Ghanem, Denise Javier, Beshoy Iskander, Jairo Aldana-Bitar et al. · 2024 · American Heart Journal
  38. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study
    Ángel Rodríguez, Jesús Reviriego, Vasilios Karamanos, Franciso J del Canizo, Nikolaos I. Vlachogiannis, Vangelis Drossinos, the ECLA Study Group · 2011 · Cardiovascular Diabetology
  39. Thiazolidinediones and the renal and hormonal response to water immersion-induced volume expansion in type 2 diabetes mellitus
    Niru Goenka, C Kotonya, Michael D. Penney, Harpal Singh Randeva, JAMES P. OʼHARE · 2008 · American Journal of Physiology-Endocrinology and Metabolism
  40. Advances in the care of lipodystrophies
    Isabel Shamsudeen, Robert Alexander Hegele · 2021 · Current Opinion in Endocrinology Diabetes and Obesity
  41. Metabolomics and Cell Therapy in Diabetes Mellitus.
    Bagher A. Larijani, Parisa Goodarzi, Moloud Payab, Sepideh Alavi-Moghadam, Fakher Rahim, Nikoo Bana, Mina Abedi, Maryam Arabi, Hossein Adibi, Kambiz Gilany et al. · 2019 · PubMed Central
  42. Rehabilitation of pioglitazone
    Robert E. J. Ryder, Ralph Anthony DeFronzo · 2015 · The British Journal of Diabetes
  43. Optimizing Antidiabetic Treatment Options for Patients with Type 2 Diabetes Mellitus and Cardiovascular Comorbidities
    Mark A. Malesker · 2008 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  44. Cytotoxicity and toxicoproteomics analysis of thiazolidinedione exposure in human‐derived cardiomyocytes
    A. Al-Sultan, Zahra Rattray, Nicholas J. W. Rattray · 2024 · Journal of Applied Toxicology
  45. Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) – A new therapeutic option?
    Marcus D. Säemann, Michael Krebs · 2010 · Wiener klinische Wochenschrift
  46. Rosiglitazone and pioglitazone aggravate doxorubicin-induced cardiomyopathy in Wistar rats
    Priyadarshan Saraogi, Krishna Kolappa Pillai, Bhulan Kumar Singh, Kiran Dubey · 2011 · Biomedicine & Aging Pathology
  47. RETRACTED: Rosiglitazone and pioglitazone aggravate doxorubicin-induced cardiomyopathy in Wistar rats
    Priyadarshan Saraogi, Krishna Kolappa Pillai, Bhulan Kumar Singh, Kiran Dubey · 2010 · Biomedicine & Pharmacotherapy · Retracted
  48. Bariatric and Metabolic Surgery in Adolescents: a Path to Decrease Adult Cardiovascular Mortality
    Andrew James Beamish, Torsten Olbers · 2015 · Current Atherosclerosis Reports
  49. Clinical Guidance for Lipodystrophy Syndromes: From Diagnosis and Work-Up to Treatment
    Donatella Gilio, Maria Cristina Foss‐Freitas, Elif A Oral · 2025 · Current Diabetes Reports
  50. Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM
    Metin Güçlü, Özen Öz Gül, Soner Cander, Oguzkaan Unal, Güven Özkaya, Emre Sarandöl, Canan Ersoy · 2015 · Journal of Diabetes Research
  51. Rosiglitazone transiently disturbs calcium homeostasis in monocytic cells
    J. Caddy, Neenu Singh, Lisa Atkin, Maninder Kaur Ahluwalia, A. Roberts, D. Lang, Andrew W. Thomas, R Webb · 2007 · Biochemical and Biophysical Research Communications
  52. Thymoquinone Therapy Improves Hyperglycemia, Erythrocyte Indices, Erythropoietin Production and Erythrocyte Osmotic Resistance in Rat Model of Streptozotocin-induced Diabetes
    Tariq Helal Ashour · 2014 · Journal of Advances in Medicine and Medical Research
  53. Thiazolidinediones and cardiovascular outcomes in type 2 diabetes
    Sonal Singh, Curt Daniel Furberg · 2008 · Heart
  54. PPARγ partial agonist GQ-16 strongly represses a subset of genes in 3T3-L1 adipocytes
    Flora Aparecida Milton, Aleksandra Čvoro, Angélica Amorim Amato, Douglas H. Sieglaff, Carly S. Filgueira, Anithachristy Sigamani Arumanayagam, Maria do Carmo Alves de Lima, Ivan Rocha Pitta, Francisco de Assis Rocha Neves, Paul Webb · 2015 · Biochemical and Biophysical Research Communications
  55. Evaluation Of Antidiabetic Activity Of Irvingia Gabonensis (Aubry-Lecomte Ex O'Rorke) Leaf And Bark In Alloxan Induced Diabetic Rats
    Ayodele Omoniyi Sulaimon, Timothy Auta, Amusat T. Hassan · 2015 · Zenodo (CERN European Organization for Nuclear Research)
  56. Diabetes
    Syed Khalid Imam · 2014 · Elsevier eBooks
  57. Pioglitazone Induces Cardiomyocyte Apoptosis and Inhibits Cardiomyocyte Hypertrophy Via VEGFR-2 Signaling Pathway
    Wenliang Zhong, Wen Jin, Shanghua Xu, Yanqing Wu, Shunxiang Luo, Minlie Liang, Lianglong Chen · 2018 · Arquivos Brasileiros de Cardiologia
  58. Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
    Eun‐Jung Rhee · 2022 · Endocrinology and Metabolism
  59. [Determination of triterpenoid acids in leaves of Eriobotrya japonica collected at in different seasons].
    Han Lv, XI Chao-peng, Jian Chen, Weilin Li · 2009 · PubMed
  60. Adverse Events Due to Oral Hypoglycemic Drugs
    Arun Nanditha, Rebeccaa Eapen Vettath · 2024 · Springer eBooks
  61. Anti-diabetic drug utilization patterns in a government hospital in Saudi Arabia
    Misbahuddin M. Rafeeq, AM Hussam, JG Zohair, MS Ziaullah · 2018 · Tropical Journal of Pharmaceutical Research
  62. Leonotis Leonurus improves the crosstalk between peripheral tissues both in vivo and in vitro
    Frank Odei-Addo, S. Ramlugon, R.‐A. Levendal, Carminita Lara Frost · 2020 · Journal of Ethnopharmacology
  63. Assessment and Reporting of Harm
    Lawrence M. Friedman, Curt Daniel Furberg, David L. DeMets, David M. Reboussin, Christopher Bull Granger, Thomas J. Moore · 2015 · Springer eBooks
  64. Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
    Singh, Sonal, Loke, Yoon K., Furberg, Curt D. · 2007 · JAMA
  65. Therapy of Diabetes Mellitus Using Experimental Animal Models
    T. S. Min, S. H. Park · 2010 · Asian-Australasian Journal of Animal Sciences
  66. Thiazolidinediones Cause Cardiotoxicity via PPARγ- Independent Mechanism
    Jingbo Jiang, James A. Balschi, Francis X. Jr McGowan, Huamei He · 2018 · InTech eBooks
  67. Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study
    Su Jin Lee, Kyoung Hwa Ha, Jung Hyun Lee, Hokyou Lee, Dae Jung Kim, Hyeon Chang Kim · 2019 · PLoS ONE
  68. Pharmacotherapy of Diabetes
    Carl Erik Mogensen · 2007 · Springer eBooks
  69. An agenda for UK clinical pharmacology: Adverse drug reactions
    Yoon Kong Loke · 2012 · British Journal of Clinical Pharmacology
  70. Tratamiento hipoglucemiante en pacientes con diabetes mellitus tipo 2 con insuficiencia cardiaca estable o cardiopatía isquémica sin insuficiencia cardiaca
    Ángeles Alonso-García, Francisco Javier García Soidán, Arturo Lisbona Gil · 2010 · Medicina Clínica
  71. Assessing and Reporting Adverse Events
    Lawrence M. Friedman, Curt Daniel Furberg, David L. DeMets · 2010 · Springer eBooks
  72. Anti-diabetic and some haematological effects of aqueous and ethanol leaf extract of Eriosema psoraleoides in alloxan-induced diabetic Wistar rats
    Florence Onyemachi Nduka, Victor Nwadiogbu Ogugua, Packer E. Joshua, Victor E. Okpachi, Sandra A. Gometi, Juliet Onyinye Nwigwe · 2018 · AFRICAN JOURNAL OF BIOTECHNOLOGY
  73. Sodium‐glucose cotransporter 2 inhibitors: A comprehensive review from cells to bedside
    B. Bagheri, Habib Yaribeygi, E. Taherifard, Azita H. Talasaz, H. Bagheri, M. Darban, R. Tabrizi, S. Najafi, M. Khodadost, M. Akbari · 2022 · Fundamental & Clinical Pharmacology
  74. Effect of Ocimum gratissimum Leaf-extract on Hematological Indices and Lipid Profile of Streptozotocin-induced Diabetic Wistar Rats
    Peter Bassey Enyievi, Bob I.A. Mgbeje, Glory Mbe Egom Nja, B.C. Edu, R.I. Ejemot-Nwa · 2020 · Pakistan Journal of Biological Sciences
  75. Oral Agents for Type-2 Diabetes
    Ronald A. Codario · 2010 · Humana Press eBooks
  76. What evidence should guide the use of thiazolidinediones?
    Matthew C. Riddle · 2010 · Nature Reviews Endocrinology
  77. Treatment with pioglitazone induced significant, reversible mitral regurgitation
    Mozhgan Dorkhan, Magnus Dencker, Anders H. Frid · 2008 · Cardiovascular Diabetology
  78. Dapagliflozin combination therapy in type 2 diabetes mellitus
    Tamer G. Yacoub · 2015 · Postgraduate Medicine
  79. Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions
    Kalie L. Tommerdahl, Alexander J. Kula, Petter Bjornstad · 2023 · Expert Opinion on Pharmacotherapy
  80. Pioglitazone—when is a prescription drug safe?
    Yoon Kong Loke, Katharina Mattishent · 2015 · Nature Reviews Urology
  81. GQ‐130, a novel analogue of thiazolidinedione, improves obesity‐induced metabolic alterations in rats: Evidence for the involvement of PPARβ/δ pathway
    Odair Alves Silva, Helder Veras Ribeiro Filho, Thayná Mendonça Avelino, Thaís Tittanegro, Ana Carolina Migliorini Figueira, Luíza Antas Rabelo, Ivan da Rocha Pitta, Saad Lahlou, Glória Isolina Boente Pinto Duarte · 2020 · Clinical and Experimental Pharmacology and Physiology
  82. In vitro antidiabetic and antioxidant properties of dioecious Morus alba (Moraceae) extracts
    Camelia Gabriela-Anca Maier, Paramita Basu, Charitha Thallapareddy · 2021 · Pharmacognosy Research
  83. Antidiabetic and Antioxidant Activities of Ipomoea staphylina Leaves in Streptozotocin (STZ) induced Diabetic Mice
    Firdous Sm, Raju Koneri · 2014
  84. Can the Electrophysiological Action of Rosiglitazone Explain its Cardiac Side Effects?
    Andrea Szebeni, Norbert Szentandrássy, Pál Pacher, J Simkó, Péter P. Nánási, Valéria Kecskeméti · 2011 · Current Medicinal Chemistry
  85. Diabetes in the elderly
    Angela Botts, Medha N. Munshi · 2008 · Current Cardiovascular Risk Reports
  86. Reversible Mitral and Aortic Regurgitation Due to Pioglitazone
    Sunil Kumar Kota, Prabhas Ranjan Tripathy, Siva Krishna Kota, Sruti Jammula, Sandip Kumar Panda, Kirtikumar D Modi · 2012 · Endocrine Practice
  87. Rosiglitazone versus pioglitazone in relation to cardiovascular disease in type 2 diabetes: primum non nocere
    Robert E. J. Ryder · 2007 · Practical Diabetes
  88. Effects of hypoglycemic agents on mortality and major cardiovascular outcomes in patients with type 2 diabetes mellitus: a narrative review [88].
    Vasco P Miranda, Mariana Rodrigues, Francisco Rocha‐Gonçalves, José Pedro L. Nunes · 2009 · PubMed
  89. MOLECULAR DOCKING OF FLINDERSINE WITH SOME TARGETS RELATED TO Β-CELLS PROTECTION
    Santiagu Stephen Irudayaraj, Antony Stalin, Veeramuthu Duraipandiyan, Savarimuthu Ignacimuthu S.J. · 2014 · International Journal for Computational Biology
  90. Heart Failure and Chronic Kidney Disease in Type 2 Diabetes
    Simona Cernea · 2016 · Journal of Interdisciplinary Medicine
  91. A REVIEW ON THIAZOLIDINEDIONES: A POTENT BIOLOGICAL AGENT
    Archana Sharma, Ramit Kapoor, Pooja Mittal, Ashish Kapoor · 2017 · International Research Journal of Pharmacy
  92. Clinical Approach to Assessment and Amelioration of Atherosclerotic Vascular Disease in Diabetes
    Ronald B Goldberg · 2020 · Frontiers in Cardiovascular Medicine
  93. Assessing the Effects of Thiazole-Carboxamide Derivatives on the Biophysical Properties of AMPA Receptor Complexes as a Potential Neuroprotective Agent
    Mohammad Qneibi, Mohammed Hawash, Sosana Bdir, Mohammad Bdair, Samia Ammar Aldwaik · 2024 · Molecules
  94. Cardiovascular adverse effects of common non-oncologic medications: from mechanisms to clinical management
    Maria Cecilia Bahit, Pilar Agudo-Quílez, José Luis Zamorano, Charles Michael Gibson · 2026 · European Heart Journal - Cardiovascular Pharmacotherapy
  95. Cardiovascular outcome trials in type 2 diabetes: A critical analysis
    Hamid Ashraf, Jamal Ahmad · 2018 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
  96. Anti-reno-haematological tenacity of Calotropis procera aqueous-methanol root extract in alloxan-induced pancrotoxic Wistar rats
    Godwin Okwudiri Ihegboro, Chimaobi James Ononamadu, Tajudeen Alowonle Owolarafe, Mujiburrahman Fadilu, Okoro Echizonachukwu Joseph · 2022 · Comparative Clinical Pathology
  97. Peroxisome proliferator-activated receptor gamma mutation in familial partial lipodystrophy type three: A case report and review of literature
    Christopher W. Wu, Hao Liu, Li-Juan Tu, Jiongyu Hu · 2024 · World Journal of Diabetes
  98. Pleural effusion caused by pioglitazone: case report
    A Munir, S Kalathil, S Nag · 2011 · Practical Diabetes
  99. Rosiglitazone
    Richard E. Gilbert · 2007 · Clinical Journal of the American Society of Nephrology
  100. Insulin Resistance Intervention After Stroke Trial of Pioglitazone
    George Ntaios, Thomas A. Kent · 2016 · Stroke